Prosecution Insights
Last updated: May 04, 2026
Application No. 17/925,948

ELECTROLYTIC SOLUTION, MAGNESIUM PRODUCTION METHOD, MAGNESIUM, AND MAGNESIUM FOIL

Final Rejection §103§112
Filed
Nov 17, 2022
Priority
May 20, 2020 — JP 2020-087831 +1 more
Examiner
WONG, EDNA
Art Unit
1795
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Murata Manufacturing Co. Ltd.
OA Round
6 (Final)
58%
Grant Probability
Moderate
7-8
OA Rounds
0m
Est. Remaining
39%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
604 granted / 1038 resolved
-6.8% vs TC avg
Minimal -19% lift
Without
With
+-19.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
40 currently pending
Career history
1078
Total Applications
across all art units

Statute-Specific Performance

§101
0.1%
-39.9% vs TC avg
§103
41.6%
+1.6% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
36.7%
-3.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1038 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is in response to the Amendment dated February 9, 2026. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office Action. Response to Arguments Election/Restrictions This application contains claims 8-10, 12-14, 16, 18 (method claims) and 11, 15, 17, 19 (product claims) drawn to an invention nonelected without traverse in the reply filed on November 4, 2023. Claim Rejections - 35 USC § 103 I. Claim(s) 1-4 have been rejected under 35 U.S.C. 103 as being unpatentable over Matsui et al. (US Patent Application Publication No. 2014/0170507 A1). The rejection of claims 1-4 under 35 U.S.C. 103 as being unpatentable over Matsui et al. has been withdrawn in view of Applicant’s amendment.1 II. Claim(s) 21 has been rejected under 35 U.S.C. 103 as being unpatentable over Matsui et al. (US Patent Application Publication No. 2014/0170507 A1) as applied to claims 1-4 above. The rejection of claim 21 under 35 U.S.C. 103 as being unpatentable over Matsui et al. as applied to claims 1-4 above has been withdrawn in view of Applicant’s amendment. III. Claim(s) 22 and 23 have been rejected under 35 U.S.C. 103 as being unpatentable over Matsui et al. (US Patent Application Publication No. 2014/0170507 A1) as applied to claims 1-4 above. The rejection of claims 22 and 23 under 35 U.S.C. 103 as being unpatentable over Matsui et al. as applied to claims 1-4 above has been withdrawn in view of Applicant’s amendment. Response to Amendment Claim Objections Claims 9, 10 and 13 would be objected to because of the following informalities:2 Claim 9 (Withdrawn) line 2, please insert the word -- the -- before the word “magnesium”. This is an instance where the article should be added to ensure proper antecedent basis for the claim terminology. line 2, please amend “mA/cm2” to -- mA/cm2 --. Claim 10 (Withdrawn) line 2, please insert the word -- the -- before the word “magnesium”. This is an instance where the article should be added to ensure proper antecedent basis for the claim terminology. Claim 13 (Withdrawn) line 2, please amend “mA/cm2” to -- mA/cm2 --. Appropriate correction is required. Claim Rejections - 35 USC § 112 I. Claims 1, 4, 22 and 24 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 lines 13-14, “a case where the electrolytic solution is a supersaturated solution at the room temperature is excluded” is new matter. The Examiner has carefully considered the entire specification as originally filed, however, there is found no literal support in the specification for the newly added limitation in amended claim 1. Applicant has not provided the page number and line numbers from the specification as to where the newly added limitations are coming from. Ex parte Grasselli, 231 USPQ 393 (Bd. App. 1983) aff’d mem. 738 F.2d 453 (Fed. Cir. 1984). II. Claims 1, 4, 22 and 24 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 lines 13-14, “a case where the electrolytic solution is a supersaturated solution at the room temperature is excluded” is indefinite because this suggests one example among many, rather than a specific, known, or previously mentioned case. Citations The prior art made of record and not relied upon is considered pertinent to applicant’s disclosure. JP 2002068746 is cited to teach that the manganese halide aqueous solution is 0.1 to 2 mol/l and the lithium compound aqueous solution is 0.05 to 1 mol/l (ρ [0042]). Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to EDNA WONG whose telephone number is (571) 272-1349. The examiner can normally be reached Monday-Friday, 7:00 AM- 3:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Luan Van can be reached at (571) 272-8521. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /EDNA WONG/Primary Examiner, Art Unit 1795 1 Applicant has shown that the region in which the electrolyte concentration specified in the present application is 0.08 mol or more exhibits a greater increase in current density in response to an increase in electrolyte concentration (Fig. 2). 2 Possible rejoinder of method claims 8-10 and 12-14.
Read full office action

Prosecution Timeline

Show 8 earlier events
Apr 04, 2025
Applicant Interview (Telephonic)
May 12, 2025
Response Filed
May 20, 2025
Final Rejection — §103, §112
Aug 22, 2025
Request for Continued Examination
Aug 26, 2025
Response after Non-Final Action
Oct 04, 2025
Non-Final Rejection — §103, §112
Feb 09, 2026
Response Filed
Mar 22, 2026
Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12612709
METHOD OF INHIBITING TARNISH FORMATION AND CORROSION
3y 3m to grant Granted Apr 28, 2026
Patent 12606926
SURFACE TREATMENT METHOD OF ALUMINUM MATERIAL
2y 6m to grant Granted Apr 21, 2026
Patent 12605488
SURFACE TREATMENT METHODS FOR CEMENTLESS IMPLANTABLE MEDICAL DEVICES
2y 4m to grant Granted Apr 21, 2026
Patent 12606919
Multi-Metal Electrocatalytic System for Methane Oxidation
2y 2m to grant Granted Apr 21, 2026
Patent 12601067
ELECTROCHEMICAL OXIDATION OF CYCLOALKENES AND CYCLOALKANES INTO ALPHA, OMEGA-DICARBOXYLIC ACIDS OR INTO KETOCARBOXYLIC ACIDS AND CYCLOALKANONE COMPOUNDS
1y 6m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

7-8
Expected OA Rounds
58%
Grant Probability
39%
With Interview (-19.1%)
3y 1m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1038 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month